Xencor Inc SEC filings XNCR

Xencor Inc has 897 filings in SEC EDGAR's recent list, going back to May 6, 2005. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Xencor Inc SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 27, 2026 Dec 31, 2025
10-K Annual report Feb 25, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
10-K/A Amended annual report Feb 24, 2025 Dec 31, 2023
ARS Annual report to shareholders Apr 24, 2024 Dec 31, 2023
10-K Annual report Feb 29, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 26, 2023 Dec 31, 2022
10-K Annual report Feb 27, 2023 Dec 31, 2022
10-K Annual report Feb 24, 2022 Dec 31, 2021
10-K Annual report Feb 24, 2021 Dec 31, 2020
10-K Annual report Feb 25, 2020 Dec 31, 2019
10-K Annual report Feb 26, 2019 Dec 31, 2018
10-K Annual report Feb 28, 2018 Dec 31, 2017
10-K Annual report Mar 1, 2017 Dec 31, 2016
10-K Annual report Mar 8, 2016 Dec 31, 2015
ARS Annual report to shareholders Apr 27, 2015 Dec 31, 2014
10-K/A Amended annual report Feb 23, 2015 Dec 31, 2014
10-K Annual report Feb 20, 2015 Dec 31, 2014
ARS Annual report to shareholders May 2, 2014 Dec 31, 2013
10-K Annual report Mar 31, 2014 Dec 31, 2013

Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
XNCR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Pasadena, CA
SEC filer status
Accelerated filer
SEC CIK
1326732

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.